2024-09-24 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets a wide range of pharmaceutical products.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):**
    * **Cumulative Return (AMGN):** 88.07%
    * **Cumulative Return (VOO):** 133.1%
    * **Lagging by:** -45.03% 
    * **Relative Lagging:** 40.79% (This means AMGN's performance has been in the 40.79th percentile of its historical performance relative to the S&P 500).

2. **Recent Price Movement:**
    * **Closing Price:** $335.61
    * **5-Day Moving Average:** $334.8
    * **20-Day Moving Average:** $330.53
    * **60-Day Moving Average:** $327.32

3. **Technical Indicators:**
    * **RSI:** 57.23 (Neutral, neither overbought nor oversold)
    * **PPO:** 0.21 (Positive, indicating potential upside)
    * **Delta_Previous_Relative_Divergence:** 0.24 (Positive, suggesting recent price movement is outpacing previous trends)
    * **Expected Return:** 9.24% (Maximum expected return over the next 5 years)

4. **Recent Earnings and Outlook:**

    | Date      | EPS        | Revenue        |
    |-----------|-------------|----------------|
    | 2024-08-07 | 1.39      | 8.39 B$        |
    | 2024-05-03 | -0.21      | 7.45 B$        |
    | 2023-10-31 | 3.23      | 6.90 B$        |
    | 2023-08-04 | 2.58      | 6.99 B$        |
    | 2024-08-07 | 2.58      | 6.99 B$        |

    * **Most Recent Earnings:**
        * **EPS:** 1.39 (Actual)
        * **Revenue:** 8.39 B$ (Actual) 
        * **Earnings were above analyst estimates.**

**Overall Analysis:**

Amgen's stock has lagged behind the S&P 500 in recent years, but it has shown signs of improvement in recent quarters.  Technical indicators are suggesting potential upside. The company's most recent earnings report beat analyst expectations, showing solid performance.  The expected return of 9.24% over 5 years suggests potential investment value.  

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. 
